Surface characterization, mechanical properties and corrosion behaviour of ternary based ZneZnOeSiO2composite coating of mild steel

Zinc coatings are obtained either from cyanide, non-cyanide alkaline or acid solutions. Because of the pollution and high cost associated with cyanide, deposition from other baths is gaining importance. In order to develop a bath with additive that could produce a quality coating is the motivation behind this present work which is surface modification of Zne8ZnOeSiO2 nano composite coating on mild steel surface by electrodeposition route. The influence of SiO2 on Zne8ZnO sulphate electrolyte on the properties and microstructure of the produced nano-coatings were investigated. The SiO2 was varied from 0 to 16wt%. The microstructure characteristics of these produced series composites coating were investigated using scanning electron microscopy couple with energy dispersive spectroscopy (SEM/EDS), X-ray diffraction and atomic force microscopy (AFM). The corrosion degradation properties in 3.65% NaCl medium were studied using potentiodynamic polarization technique and characterized by high resolution optical microscope (HR-OPM). The hardness and wear of the composite coating were measured with high diamond microhardness tester and dry abrasive MTR-300 testers respectively. The results showed that average hardness value of 142.5 and 251.2HV and corrosion rate of 0.13088 and 0.00122 mm/yr were obtained for the 0 and 16wt% SiO2 in Zne8ZnO. The work have established that upto 16% SiO2 in Zne8ZnO composite coating on mild steel can be used in improving the microhardness, wear loss and corrosion resistance of mild stee

The expression of EZH2 and H3K27me3 in human samples.

<p>Representative EZH2 and H3K27me3 immunohistochemical staining in renal cell carcinoma (200×magnification). (A-H) Positive EZH2 (black arrow) and H3K27me3 (white arrow) display a nuclear staining. (A) negative in RCC (E) negative in none tumor tissue (B-D) EZH2 positive (F-H) H3K27me3 positive (B) (F) staining intensity index-1socre (C) (G) staining intensity index-2 score (D) (H) staining intensity index-3 score (I) the expression of EZH2 and H3K27me3 was detected in all 10 cases of RCC tissues compared to adjacent non-RCC tissues. N, non-RCC tissue; T, RCC tissue.</p

Comparisons of the receiver operating characteristic (ROC) curves for prediction of survival by the EZH2 score, TNM stage, and H3K27me3 score.

<p>(A) (E) DFS, (B) (F) OS in the training set. (C) (G) DFS, (D) (H) OS in the validation set. (A-D) the area under the ROC curves (AUROC) of EZH2 score versus the AUROC of TNM stage, or H3K27me3 score. (E-H) the AUROC of the combined EZH2 and TNM stage model versus the AUROC of the TNM stage or EZH2 expression alone model.</p

Kaplan-Meier analysis of disease-free survival (DFS) in renal cell carcinoma according to expression of the EZH2 or H3K27me3 score.

<p>(A), (D) all patients in the training set. (B), (E) patients with I+II stage disease in the training set. (C), (F) patients with III+IV stage disease in the training set. (G), (J) all patients in the validation set. (H), (K) patients with I+II stage disease in the validation set. (I), (L) patients with III+IV stage disease in the validation set. </p

Kaplan-Meier analysis of overall survival (OS) in renal cell carcinoma according to expression of the EZH2 or H3K27me3 score.

<p>(A), (D) all patients in the training set. (B), (E) patients with I+II stage disease in the training set. (C), (F) patients with III+IV stage disease in the training set. (G), (J) all patients in the validation set. (H), (K) patients with I+II stage disease in the validation set. (I), (L) patients with III+IV stage disease in the validation set. </p

Additional file 1: Figure S1. of The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients

Kaplan–Meier analysis to assess prognostic value of CXCR2 in some clinicopathological factors. (A) T1 stage, n = 80, p = 0.386. (B) T2 stage, n = 50, p = 0.803. (C) N2 stage, n = 70, p = 0.124. (D) N3 stage, n = 122, p = 0.162. (E) Lauren intestinal type, n = 224, p < 0.01. (F) Lauren diffuse type, n = 133, p = 0.012. (JPEG 322 kb

Additional file 1: Table S1. of Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma

Univariate analyses of characteristics associated with overall survival and recurrence-free survival. (DOC 58 kb

Additional file 2: Figure S2. of The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients

COX analysis assesses prognostic value of CXCR2 with hazard ratios for OS in subgroups. T3 (n = 65, HR: 3.326, 95 % CI: 1.522-7.267, p = 0.003), T4 (n = 182, HR: 1.768, 95 % CI: 1.178-2.652, p = 0.006), N0 (n = 128, HR: 2.782, 95 % CI: 1.389-5.574, p = 0.004), TNM I + II (n = 158, HR: 2.713, 95 % CI: 1.404-5.241, p = 0.003), TNM III + IV (n = 199,HR: 1.623, 95 % CI: 1.126-2.340, p = 0.01), well and moderate differentiation (n = 147, HR: 2.159, 95 % CI: 1.262-3.691, p = 0.005), poor differentiation (n = 210, HR: 2.158, 95 % CI: 1.448-3.217, p < 0.001), Lauren intestinal type (n = 224, HR: 2.573, 95 % CI: 1.672-3.958, p < 0.001), Lauren diffuse type (n = 133, HR: 1.834, 95 % CI: 1.137-2.960, p = 0.014). (JPEG 302 kb

Additional file 1: of Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

Table S1. Association between CD8+ T cells infiltration and patient characteristics. (DOC 64 kb

Additional file 2: of Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

Figure S1. Association between CD8+ T cells and overall survival in the discovery set and validation set. (A,C) Kaplan-Meier analysis of overall survival in the discovery set and validation set based on CD8+ T cells infiltration (B,D) Kaplan-Meier analysis of overall survival in the discovery set and validation set based on combination of TIMs and CD8+ T cells infiltration. (TIFF 652 kb